Results of Precision Biologics Phase 2 Colorectal Cancer Study Published in Clinical Cancer Research
Precision Biologics announces that the results of the Phase II Clinical Trial using its lead...
30Apr
01Mar
Precision Biologics to Deliver two Oral Presentations on our Clinical and Scientific Programs at the World Immunotherapy Conference, March 2-4, 2020, San Diego, CA
Dr Massimo Fantini, Senior Scientist is Presenting the following Talk entitled: "Mechanisms of action of...
06Nov
SITC 2019
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...
15Oct
Novel Targets Of Neoantigens In Monoclonal Antibodies
Philip M. Arlen, M.D. Summary: Target is broadly expressed in multiple solid tumors. Exhibits both ADCC and CDC...
01Nov
The National Cancer Institute Opens Clinical Trial Testing Safety and Dosing of NEO-201 Antibody in Patients with Advanced Cancer
Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer NIH 11/01/2018 Patients...
08Jan
Precision Biologics manuscript on our NEO-201 Antibody article published in Frontiers in Immunology
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
02Apr
Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical Research
Rockville, MD, April 2, 2017 - Precision-Biologics Inc.
29Sep
Dr. Philip Arlen to Speak at Biomarkers & Precision Medicine USA Congress
Dr. Philip Arlen to Speak at Biomarkers & Precision Medicine USA Congress - 3-4 October 2016,...
29Sep
Dr. Philip Arlen to Speak at Immune Profiling World Congress
Dr. Philip Arlen to Speak at Immune Profiling World Congress – 11-12 October 2016, Fairmont...
16Jun
Read more...